Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation

Sydney X. Lu, Lucy W. Kappel, Anne Marie Charbonneau-Allard, Renée Atallah, Amanda M. Holland, Claire Turbide, Vanessa M. Hubbard, Jimmy A. Rotolo, Marsinay Smith, David Suh, Christopher King, Uttam K. Rao, Nury Yim, Johanne L. Bautista, Robert R. Jenq, Olaf Penack, Il Kang Na, Chen Liu, George Murphy, Onder AlpdoganRichard S. Blumberg, Fernando Macian-Juan, Kathryn V. Holmes, Nicole Beauchemin, Marcel R M van den Brink

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models. Methods: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1-/- T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25hi, CD62Llo). Additionally, Ceacam1-/- CD8 T cells had greater expression of the gut-trafficking integrin α4β7, though both CD4 and CD8 T cells were found increased numbers in the gut post-transplant. Ceacam1-/- recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1-/- mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1+ lymphoma model was improved in animals receiving Ceacam1-/- vs. control T cells. Conclusions: We conclude that Ceacam1 regulates T cell activation, GVHD target organ damage, and numbers of donor T cells in lymphoid organs and GVHD target tissues. In recipients of allo-BMT, Ceacam1 may also regulate tissue radiosensitivity. Because of its expression on both the donor graft and host tissues, this suggests that targeting Ceacam1 may represent a potent strategy for the regulation of GVHD and GVT after allogeneic transplantation.

Original languageEnglish (US)
Article numbere21611
JournalPLoS One
Volume6
Issue number7
DOIs
StatePublished - 2011

Fingerprint

bone marrow transplant
Carcinoembryonic Antigen
Homologous Transplantation
Cell Adhesion Molecules
Graft vs Host Disease
Bone Marrow Transplantation
cell adhesion
Grafts
T-cells
Tumors
Bone
antigens
Transplants
T-lymphocytes
neoplasms
T-Lymphocytes
Neoplasms
Chemical activation
Tissue
Transplantation (surgical)

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lu, S. X., Kappel, L. W., Charbonneau-Allard, A. M., Atallah, R., Holland, A. M., Turbide, C., ... van den Brink, M. R. M. (2011). Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. PLoS One, 6(7), [e21611]. https://doi.org/10.1371/journal.pone.0021611

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. / Lu, Sydney X.; Kappel, Lucy W.; Charbonneau-Allard, Anne Marie; Atallah, Renée; Holland, Amanda M.; Turbide, Claire; Hubbard, Vanessa M.; Rotolo, Jimmy A.; Smith, Marsinay; Suh, David; King, Christopher; Rao, Uttam K.; Yim, Nury; Bautista, Johanne L.; Jenq, Robert R.; Penack, Olaf; Na, Il Kang; Liu, Chen; Murphy, George; Alpdogan, Onder; Blumberg, Richard S.; Macian-Juan, Fernando; Holmes, Kathryn V.; Beauchemin, Nicole; van den Brink, Marcel R M.

In: PLoS One, Vol. 6, No. 7, e21611, 2011.

Research output: Contribution to journalArticle

Lu, SX, Kappel, LW, Charbonneau-Allard, AM, Atallah, R, Holland, AM, Turbide, C, Hubbard, VM, Rotolo, JA, Smith, M, Suh, D, King, C, Rao, UK, Yim, N, Bautista, JL, Jenq, RR, Penack, O, Na, IK, Liu, C, Murphy, G, Alpdogan, O, Blumberg, RS, Macian-Juan, F, Holmes, KV, Beauchemin, N & van den Brink, MRM 2011, 'Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation', PLoS One, vol. 6, no. 7, e21611. https://doi.org/10.1371/journal.pone.0021611
Lu, Sydney X. ; Kappel, Lucy W. ; Charbonneau-Allard, Anne Marie ; Atallah, Renée ; Holland, Amanda M. ; Turbide, Claire ; Hubbard, Vanessa M. ; Rotolo, Jimmy A. ; Smith, Marsinay ; Suh, David ; King, Christopher ; Rao, Uttam K. ; Yim, Nury ; Bautista, Johanne L. ; Jenq, Robert R. ; Penack, Olaf ; Na, Il Kang ; Liu, Chen ; Murphy, George ; Alpdogan, Onder ; Blumberg, Richard S. ; Macian-Juan, Fernando ; Holmes, Kathryn V. ; Beauchemin, Nicole ; van den Brink, Marcel R M. / Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. In: PLoS One. 2011 ; Vol. 6, No. 7.
@article{12cd1e7fe84c4112b9c16a55ec506431,
title = "Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation",
abstract = "Background: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models. Methods: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1-/- T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25hi, CD62Llo). Additionally, Ceacam1-/- CD8 T cells had greater expression of the gut-trafficking integrin α4β7, though both CD4 and CD8 T cells were found increased numbers in the gut post-transplant. Ceacam1-/- recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1-/- mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1+ lymphoma model was improved in animals receiving Ceacam1-/- vs. control T cells. Conclusions: We conclude that Ceacam1 regulates T cell activation, GVHD target organ damage, and numbers of donor T cells in lymphoid organs and GVHD target tissues. In recipients of allo-BMT, Ceacam1 may also regulate tissue radiosensitivity. Because of its expression on both the donor graft and host tissues, this suggests that targeting Ceacam1 may represent a potent strategy for the regulation of GVHD and GVT after allogeneic transplantation.",
author = "Lu, {Sydney X.} and Kappel, {Lucy W.} and Charbonneau-Allard, {Anne Marie} and Ren{\'e}e Atallah and Holland, {Amanda M.} and Claire Turbide and Hubbard, {Vanessa M.} and Rotolo, {Jimmy A.} and Marsinay Smith and David Suh and Christopher King and Rao, {Uttam K.} and Nury Yim and Bautista, {Johanne L.} and Jenq, {Robert R.} and Olaf Penack and Na, {Il Kang} and Chen Liu and George Murphy and Onder Alpdogan and Blumberg, {Richard S.} and Fernando Macian-Juan and Holmes, {Kathryn V.} and Nicole Beauchemin and {van den Brink}, {Marcel R M}",
year = "2011",
doi = "10.1371/journal.pone.0021611",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation

AU - Lu, Sydney X.

AU - Kappel, Lucy W.

AU - Charbonneau-Allard, Anne Marie

AU - Atallah, Renée

AU - Holland, Amanda M.

AU - Turbide, Claire

AU - Hubbard, Vanessa M.

AU - Rotolo, Jimmy A.

AU - Smith, Marsinay

AU - Suh, David

AU - King, Christopher

AU - Rao, Uttam K.

AU - Yim, Nury

AU - Bautista, Johanne L.

AU - Jenq, Robert R.

AU - Penack, Olaf

AU - Na, Il Kang

AU - Liu, Chen

AU - Murphy, George

AU - Alpdogan, Onder

AU - Blumberg, Richard S.

AU - Macian-Juan, Fernando

AU - Holmes, Kathryn V.

AU - Beauchemin, Nicole

AU - van den Brink, Marcel R M

PY - 2011

Y1 - 2011

N2 - Background: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models. Methods: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1-/- T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25hi, CD62Llo). Additionally, Ceacam1-/- CD8 T cells had greater expression of the gut-trafficking integrin α4β7, though both CD4 and CD8 T cells were found increased numbers in the gut post-transplant. Ceacam1-/- recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1-/- mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1+ lymphoma model was improved in animals receiving Ceacam1-/- vs. control T cells. Conclusions: We conclude that Ceacam1 regulates T cell activation, GVHD target organ damage, and numbers of donor T cells in lymphoid organs and GVHD target tissues. In recipients of allo-BMT, Ceacam1 may also regulate tissue radiosensitivity. Because of its expression on both the donor graft and host tissues, this suggests that targeting Ceacam1 may represent a potent strategy for the regulation of GVHD and GVT after allogeneic transplantation.

AB - Background: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models. Methods: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1-/- T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25hi, CD62Llo). Additionally, Ceacam1-/- CD8 T cells had greater expression of the gut-trafficking integrin α4β7, though both CD4 and CD8 T cells were found increased numbers in the gut post-transplant. Ceacam1-/- recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1-/- mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1+ lymphoma model was improved in animals receiving Ceacam1-/- vs. control T cells. Conclusions: We conclude that Ceacam1 regulates T cell activation, GVHD target organ damage, and numbers of donor T cells in lymphoid organs and GVHD target tissues. In recipients of allo-BMT, Ceacam1 may also regulate tissue radiosensitivity. Because of its expression on both the donor graft and host tissues, this suggests that targeting Ceacam1 may represent a potent strategy for the regulation of GVHD and GVT after allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=79960013545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960013545&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0021611

DO - 10.1371/journal.pone.0021611

M3 - Article

C2 - 21760897

AN - SCOPUS:79960013545

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e21611

ER -